The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Optimal approach to first-line therapy in myelofibrosis
Francesco Passamonti
• 11 Jun 2022
Francesco Passamonti, MD, University of Insubria, Varese, Italy, discusses the first-line treatment of myelofibrosis (MF), commenting on the use of hematopoietic stem cell transplantation (HSCT) and JAK inhibitors like ruxolitinib and fedratinib. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
